The QualityStocks Daily Thursday, February 2nd, 2023

Today's Top 3 Investment Newsletters

QualityStocks(VINO) $5.4000 +339.02%

MarketClub Analysis(BPTS) $0.7100 +73.13%

Investopedia(ALGN) $359.8800 +27.38%

The QualityStocks Daily Stock List

Gaucho Group Holdings (VINO)

QualityStocks, MarketClub Analysis, StockWireNews, StockStreetWire, Small Cap Firm, Penny Picks, Fierce Analyst, Damn Good Penny Picks, BeatPennyStocks and AwesomeStocks reported earlier on Gaucho Group Holdings (VINO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gaucho Group Holdings Inc. (NASDAQ: VINO) is a holding firm that is focused on investing in, developing and operating real estate projects in Argentina.

The firm has its headquarters in Miami Beach, Florida and was founded in 1999, on April 5th by Scot L. Mathis. Prior to its name change in March 2019, the firm was known as Algodon Group Inc. It operates in the real estate sector, under the real estate owners and developers’ plus sub-developers’ sub-industry. The firm serves consumers in Argentina as well as in the U.S.

The company identifies and develops investments in the luxury property, hospitality and boutique hotels markets as well in the other lifestyle businesses, like real estate development, tennis, golf and wine production and distribution. It conducts its business in Argentina through Algodon Wine Estates S.R.L, Algodon Properties II S.R.L., the Algodon Recoleta S.R.L., Algodon Global Properties LLC and InvestProperty Group LLC.

The enterprise also operates and owns subdivided property for residential development, a winery and golf resort with hotel, dining and tennis court amenities known as Algodon Wine Estates, which is located in Mendoza and a luxury boutique hotel located in Buenos Aires known as Algodon Mansion. The company distributes wines in Europe via its UK entity and also sells and distributes accessories and high-end luxury fashion products via an e-commerce platform.

The firm recently launched its Amazon Storefront in Buenos Aires, which will enable them to expand their global profile while allowing them to reach more consumers, which will increase the firm’s revenue while also bringing more investors into the firm.

Gaucho Group Holdings (VINO), closed Thursday's trading session at $5.4, up 339.0244%, on 39,842,469 volume. The average volume for the last 3 months is 1.306M and the stock's 52-week low/high is $0.98/$35.88.

OptimumBank (OPHC)

Wall Street Resources, OTCPicks, StockMarketWatch, Penny Stock Rumble, StocksImpossible, Broad Street, Buzz Stocks, First Penny Picks, HotOTC, Market Report, Investing Futures, MarketBeat, OTCBB Journal, Penny Pick Finders, PennyStockProphet, Profitable Trader Authority, QualityStocks, StockOnion, The Stock Prophet, TradersPro and OTCtipReporter reported earlier on OptimumBank (OPHC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OptimumBank Holdings, Inc. (NASDAQ: OPHC) is a bank holding firm that is engaged in the provision of a range of consumer and commercial banking services to businesses and individuals.

The firm has its headquarters in Fort Lauderdale, Florida and was incorporated in 2004, on March 23rd. It operates as part of the banks-regional industry, under the financial services sector. The firm serves consumers in the United States, with a focus on those in the state of Florida.

The company focuses on traditional in-person banking with business and consumers residing in South Florida. It operates as the bank holding company for OptimumBank focused on the ownership and operation of the bank. The bank is a Florida state-chartered bank, with deposits insured by the Federal Deposit Insurance Corporation (FDIC). The company has 2 banking offices located in Broward County, Florida.

The enterprise accepts demand interest-bearing and noninterest-bearing, savings, money market, NOW, and time deposit accounts, as well as certificates of deposit; and offers residential and commercial real estate, multi-family real estate, commercial, land and construction, and consumer loans, as well as lending lines for working capital needs. It also offers debit and ATM cards; investment, cash management, notary, and night depository services; and direct deposits, money orders, cashier's checks, domestic collections, and banking by mail, as well as internet banking services.

The firm recently announced its latest financial results, with its Chairman noting that they remained focused on growing and strengthening its pipeline of lending opportunities. This will help to better meet consumer needs and bring in additional revenues into the firm.

OptimumBank (OPHC), closed Thursday's trading session at $4.115, off by 0.363196%, on 6,086 volume. The average volume for the last 3 months is 21.24M and the stock's 52-week low/high is $3.33/$4.8731.

Metalpha Technology (MATH)

We reported earlier on Metalpha Technology (MATH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Metalpha Technology Holding Ltd (NASDAQ: MATH) is a holding firm involved in the supply chain management platform services business in China.

The firm has its headquarters in Wan Chai, Hong Kong and was incorporated in 2015. Prior to its name change in November 2022, the firm was known as Dragon Victory International Ltd. It operates as part of the internet content and information industry, under the communication services sector. The firm serves consumers in the People’s Republic of China.

The company’s operating segment include Metalpha; Longyun; Dacheng Liantong and Others. It generates most of its revenue from the Dacheng Liantong segment.

The enterprise provides incubation services and financial services to entrepreneurs and business entities with funding needs utilizing its crowdfunding platform. It also offers customized cryptocurrency derivative products as well as auto-parts service operation to provide one-stop services serving auto-repair shops seeking and transacting with auto-parts suppliers. This is in addition to providing an online crowdfunding platform, 5etou (, which enables projects searching for funding to connect with funding sources. In addition to the operation of its funding platforms, the enterprise provides business incubation services to the projects utilizing its platform for their projects, at the election of the projects.

The firm, which is committed to delivering the best structured derivative products to cryptocurrency market participants, remains focused on expanding its presence in digital asset wealth management with its partners. This will not only extend its consumer reach but also generate significant value for its shareholders.

Metalpha Technology (MATH), closed Thursday's trading session at $0.61, up 9.319%, on 49,325 volume. The average volume for the last 3 months is 6.781M and the stock's 52-week low/high is $0.4282/$1.41.

Lipella Pharmaceuticals (LIPO)

StockWireNews, StockStreetWire, Small Cap Firm, PennyStockScholar, PennyStockProphet, Fierce Analyst and 247 Market News reported earlier on Lipella Pharmaceuticals (LIPO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) is a clinical-stage biotechnology firm that is focused on the development of drugs through the reformulation of active agents in existing generic drugs and optimizing these reformulations for a range of applications.

The firm has its headquarters in Pittsburgh, Pennsylvania and was incorporated in 2005 by Michael Chancellor, Jonathan Kaufman and Leaf Huang. It operates as part of the biotechnology industry, under the healthcare sector. The firm primarily serves consumers in the United States.

The company mainly focuses on supportive care to cancer survivors who acquire hemorrhagic cystitis (radiation cystitis), when hemorrhagic cystitis occurs after pelvic radiation, as well as improved surveillance and imaging of patients with a history of transitional cell carcinoma.

The enterprise’s pipeline is comprised of LP-08, which comprises of Sphingomyelin Phospholipid bilayers separated by aqueous compartments; and LP-09, a liposomal formulation of Botulinum toxin. It also develops a formulation dubbed LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. This formulation is in phase 2a clinical trials for patients with radiation-induced hemorrhagic cystitis. In addition to this, it develops LP-310, a formulation of tacrolimus for the treatment of oral lichen planus.

The company recently announced results from its LP-10 candidate trial, with its CEO noting that they were one step closer to providing first-in-class treatment for the cancer survivor community with hemorrhagic cystitis. The success and approval of its formulations will not only benefit patients with this indication, but also bring in additional investments into the company.

Lipella Pharmaceuticals (LIPO), closed Thursday's trading session at $2.74, up 10.4839%, on 219,596 volume. The average volume for the last 3 months is 346,716 and the stock's 52-week low/high is $2.31/$7.72.

Capstone Green Energy (CGRN)

InvestorPlace reported earlier on Capstone Green Energy (CGRN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Capstone Green Energy Corp. (NASDAQ: CGRN) (FRA: TBN2) is a company focused on the development, manufacture, marketing and servicing of microturbine technology solutions for use in stationary distributed power generation and distribution networks applications globally.

The firm has its headquarters in Van Nuys, California and was incorporated in 1988. Prior to its name change in April 2021, the firm was known as Capstone Turbine Corp. It operates as part of the specialty industrial machinery industry, under the industrials sector. The firm serves consumers around the globe.

The enterprise provides microturbines, components, and accessories for various applications, including cogeneration combined heat and power (CHP), integrated CHP, and combined cooling, heat, and power, as well as renewable energy, natural resources, and critical power supply. Its microturbines are also used as battery charging generators for use in hybrid electric vehicles. It also offers different accessories, including rotary gas compressors with digital controls; integrated heat recovery modules for CHP applications; dual mode controllers that allow automatic transition between grid connect and stand-alone modes; batteries with digital controls for stand-alone or dual-mode operations; power servers for multipacked installations; protocol converters for internet access; packaging options; and miscellaneous parts, such as frames, exhaust ducting, backflow dampers, and installation hardware. In addition, the enterprise provides rental solutions and aftermarket spare parts. Further, it offers energy conversion products including hybrid energy stations, baker hughes, and industrial gas turbines; hydrogen energy solutions, such as hydrogen-based combined heat and power products; and energy storage products comprising microgrid storage systems and lithium-ion battery energy storage systems. The enterprise markets and sells its products primarily through distributors and original equipment manufacturers.

The company, which recently announced its latest financial results showing increases in its revenues, remains committed to creating value for its shareholders.

Capstone Green Energy (CGRN), closed Thursday's trading session at $1.82, off by 10.7843%, on 262,038 volume. The average volume for the last 3 months is 44,416 and the stock's 52-week low/high is $1.29/$4.46.

Visionary Education Technology Holdings (VEDU)

We reported earlier on Visionary Education Technology Holdings (VEDU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) is a holding firm that is engaged in the provision of private in-person and online educational programs and services to Canadian and international students that reside in Canada and globally.

The firm has its headquarters in Markham, Canada and was incorporated in 2013 by Fan Zhou. Prior to its name change in March 2021, the firm was known as 123 Natural Food Ontario Limited. It operates as part of the education and training services industry, under the consumer defensive sector. The firm serves consumers around the globe.

The company’s objective is to provide high-quality education. It operates as a subsidiary of 3888 Investment Group Limited. It provides services through the following business clusters: Credential-oriented education, vocational education and education services. The three lines of business are inter-beneficial. These businesses are run through VEDU’s 12 affiliates, including Farvision Education Group Inc., Visionary Education Services & Management Inc., Visionary Study Abroad and Immigration Services Inc., Farvision Human Resource Service Company Inc., NeoCanaan Investment Corp., Canada Animation Industry Group Inc., Farvision Development Group Inc., Toronto eSchool Inc., Toronto Art Academy Inc., Lowell Academy, Conbridge College of Business and Technology, Princeton Career Education Group Inc.

The enterprise's educational programs include Ontario secondary school diploma, career-oriented two-year college and four-year university diploma programs, vocational education programs, and master programs. It also provides educational services, such as immigration and study visa, student housing, career guidance, internship, and entrepreneurship guidance.

The firm, which recently appointed a new CEO and COO, remains focused on expanding its business vertically to capture more growth opportunities. This will positively influence its long-term growth and shareholder value.

Visionary Education Technology Holdings (VEDU), closed Thursday's trading session at $0.7275, off by 3%, on 24,319 volume. The average volume for the last 3 months is 13,793 and the stock's 52-week low/high is $0.3601/$28.00.

NextPlat Corp. (NXPL)

The Stock Dork and QualityStocks reported earlier on NextPlat Corp. (NXPL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, recently announced that its 2023 Annual Meeting of Stockholders will be held in a completely virtual format via webcast on Wednesday, May 31, 2023. Shareholders of record as of the close of business on April 6, 2023, shall be entitled to vote at the annual meeting and any adjournment thereof. In accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), any stockholder proposal intended to be considered for inclusion in NextPlat’s proxy materials for the 2023 Annual Meeting must comply with all applicable SEC rules and be delivered to, or mailed to and received at, the company’s executive offices, attention: corporate secretary, on or before the close of business on March 1, 2023, as detailed in the press release. In addition, to comply with the universal proxy rules under Rule 14a-19 of the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other than the company's nominees must provide notice that sets forth the information required by Rule 14a-19 no later than April 1, 2023.

To view the full press release, visit

About NextPlat Corp.

NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets for physical and digital assets. The company intends to collaborate with businesses, optimizing their ability to sell their goods online, domestically and internationally, and enabling customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications services division through its Global Telesat Communications Ltd and Orbital Satcom Corp business units that offer voice, data, tracking, and IoT services to customers worldwide through multiple global storefronts.

NextPlat Corp. (NXPL), closed Thursday's trading session at $1.56, up 1.9608%, on 49,367 volume. The average volume for the last 3 months is 78,068 and the stock's 52-week low/high is $1.2115/$3.52.

Steakholder Foods Ltd. (STKH)

We reported earlier on Steakholder Foods Ltd. (STKH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Arik Kaufman, CEO of Israel-based Steakholder Foods (NASDAQ: STKH), was featured in a recent Forbes article titled “Steakholder Foods Machine Prints Cultivated Fish That You Can Eat.” Among other highlights, the article shines a light on how Steakholder is working with Umami Meats of Singapore to develop 3D-printed structured eel and grouper products.

It’s “made up of muscle and fat tissue grown from animal cells and being developed to be indistinguishable from farm-raised meat in taste, texture and smell,” an excerpt from the Steakholder website explains. “The difference, however, is cultured meat’s potential to transform the meat industry by being more sustainable and eco-friendly than farm-raised meat.”

According to Kaufman, the U.S. fish market is huge and very attractive. He believes that the market will get used to these cultured fish products much, much sooner than other products. Kaufman predicts, “In the end, you’ll see a (fish) product that will be exactly the same, exactly the same. Not almost the same. Exactly the same.”

To view the full article, visit

About Steakholder Foods Ltd.

Steakholder Foods Ltd., formerly MeaTech 3D Ltd., is an international deep-tech food company at the forefront of the cultured meat revolution. The company initiated activities in 2019 and is listed on the Nasdaq Capital Market under the ticker “STKH” (formerly MITC). Steakholder Foods maintains facilities in Rehovot, Israel and Antwerp, Belgium and has recently expanded activities to the US.

The company is developing a slaughter-free solution for producing a variety of beef, chicken, pork, and seafood products — both as raw materials and whole cuts — as an alternative to industrialized farming and fishing. With its membership in the UN Global Compact, Steakholder Foods is committed to act in support of issues embodied in the United Nations Sustainable Development Goals (SDGs) which include strengthening food security, decreasing carbon footprint, and conserving water and land resources. For more information, visit the company’s website at

Steakholder Foods Ltd. (STKH), closed Thursday's trading session at $1.02, up 3.0303%, on 98,636 volume. The average volume for the last 3 months is 5.131M and the stock's 52-week low/high is $0.61/$6.10.

Genius Group Limited (GNS)

INO Market Report, MarketClub Analysis, The Stock Dork, QualityStocks, Wall St. Warrior, Money Wealth Matters and 247 Market News reported earlier on Genius Group Limited (GNS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Genius Group (NYSE American: GNS), a leading entrepreneur edtech and education group, today announced a plan, approved by its board, for a $10 blockchain-based digital discount coupon (non-fungible token “NFT”) per ordinary share to all shareholders. “Our investors have traditionally been retail investors who began as our students and partners, and we have had a history of providing rewards to them to acknowledge their support,” said Roger Hamilton, CEO of Genius Group. “With this $10 NFT coupon per share reward, investors gain the additional benefit of participation in both Upstream’s blockchain-powered stock exchange, where shares can be individually verified. They also benefit from a free account on GeniusU, where they can join our Entrepreneur Campus or Investor Campus to connect with our 4.3 million students around the world, giving additional opportunity to learn, connect and attend Genius Group’s 2023 Impact Investor Summit and Global Entrepreneur Summit.”

To view the full press release, visit

About Genius Group Limited.

Genius Group is a world-leading entrepreneur edtech and education group, with a mission to disrupt the current education model with a student-centered, life-long learning curriculum that prepares students with the leadership, entrepreneurial and life skills to succeed in today’s market. The group has a user base of 4.3 million in 200 countries, ranging from ages 0 to 100. For more information, visit

Genius Group Limited (GNS), closed Thursday's trading session at $7.09, up 33.7736%, on 52,143,622 volume. The average volume for the last 3 months is 260,323 and the stock's 52-week low/high is $0.301/$36.7499.

Atlis Motor Vehicles Inc. (AMV)

Money Wealth Matters, QualityStocks, The Stock Dork, MarketBeat and 247 Market News reported earlier on Atlis Motor Vehicles Inc. (AMV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A week ago, the biggest manufacturer in the world — Toyota — finally acknowledged that electric vehicles are the way of the future when it issued two significant statements. However, it might be a little bit late for a company that revolutionized manufacturing 50 years ago.

The first revelation was about Toyota creating a committed electric vehicle platform following its terrible, ill-fated BZ4X venture. The next was about Akio Toyoda, the current CEO of Toyota, stepping down in April, paving the way for a new leadership team that will propel Toyota into a new chapter of what the ideal transportation system should look like.

Toyota offers little in a market that is transforming swiftly. All-electric vehicle sales in Germany as well as in the United Kingdom hit 33% in December, rising from no more than 10% in the two countries just two years prior. In December of last year, BEVs accounted for 25% of the Chinese market, compared to only 5% over the previous two years.

Due to the complexity of the automotive industry, expanding current production is significantly simpler and quicker than creating new lines of production for novel items. Considering that only 0.2% of Toyota’s manufacturing is made up of electric vehicles, this presents a serious issue. Even though Toyota is the biggest automaker across the globe, it isn’t among the 20 top producers of electric vehicles.

As of October, Toyota had sold approximately 14,000 BEVs worldwide, a rate of production below 20,000 units annually, compared to BYD’s 911,140 and Tesla’s 1,310,000 BEVs in 2022. In the UK and Germany, completely electric vehicles currently make up one-third of new vehicle sales. As the year ends, this might reach 50%. In Norway, the BEVs’ sales market share increased from 30% in 2018 to 80% in 2022. That translates into a 50% market share in only five years. That means Toyota will lose approximately one-third of the market it can serve in these nations.

Given the rapid growth of the electric vehicle market, before Toyota launches its electric vehicle lineup in 2027 or 2028, BEVs will account for almost 50% of all new vehicle sales, and practically none of these vehicles will come from Toyota.

For Toyota, the situation is significantly worse. As customers become more conscious of the transformation going on, Cathy Wood of Ark Invest forecasts that all-electric vehicle sales will account for 90% of auto sales worldwide in 2027, collapsing the demand for gas-powered vehicles.

Will Toyota make a miraculous shift to electric vehicles? It is challenging to increase car production significantly. Despite an unprecedented growth rate, Tesla needed nine years to comfortably produce one million electric vehicles per year. Assuming Toyota can produce BEVs at the same rate as Tesla, BEV output will reach only a million units in 2031, which would still amount to a 90% decline in Toyota’s sales.

Toyota’s ability to withstand the present EV revolution is unclear. This is the sobering reality that Koji Sato, Toyota’s new CEO, must face as startups such as Atlis Motor Vehicles Inc. (NASDAQ: AMV) position themselves to exploit any gaps that the legacy carmakers delay to leverage.

Atlis Motor Vehicles Inc. (AMV), closed Thursday's trading session at $3.3, up 4.4304%, on 783,993 volume. The average volume for the last 3 months is 3.555M and the stock's 52-week low/high is $2.26/$243.99.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The past couple of years have seen a surge in psychedelic research that has revealed potential therapeutic benefits in using hallucinogenic drugs such as ketamine and psilocybin to treat mental health issues. Although most of this research is in its infancy due to prohibitionist laws that have prevented psychedelic research for decades, the findings are extremely promising.  Researchers have found that even a single dose of a psychedelic such as ketamine can result in profound and long-lasting mental health benefits.

As such, Big Pharma and investors are pouring millions of dollars into the research and development of psychedelic-assisted therapies. With psychedelics growing more popular by the day amid increased research and legislative action, there have been fears that using drugs such as ketamine for therapeutic purposes could result in addiction.

Because of ketamine’s hallucinogenic effects, it has a significant potential for addiction when used regularly and in unsupervised conditions. And since ketamine causes certain chemical changes in the brain when abused, overcoming a ketamine addiction without professional help can be quite difficult.

Fortunately, ketamine does not result in any kind of addiction when it is administered under the supervision of a qualified physician to treat a mental disorder, including depression. Ketamine infusions in medical settings rarely, if ever, result in addiction because doctors are extremely careful with administration methods, dosing amounts and dosing frequency to eradicate the potential for addiction.

Over the past few years, psychedelics have exhibited significant potential as a safe, effective and long-term treatment for a range of mental conditions, including bipolar disorder, depression, PTSD, postpartum disorders, suicidal ideation and anxiety.

On top of its mental health benefits, ketamine has also been used for years for its sedative, analgesic, anesthetic and amnestic properties. It is a safe and effective sedation option for children in the ER and is especially effective in short and painful medical procedures that call for patient immobilization.

Ketamine is generally safe to use in controlled medical settings but presents a significant risk of addiction when taken recreationally. As such, physicians have used the psychedelic drug for years in medical procedures with zero cases of life-threatening addiction.

This means that you will have a near-zero chance of developing an addiction if you receive ketamine infusions under the supervision of a medical professional to treat a mental health condition. Your risk for abuse and addiction only increases if you step away from the medical setting and take ketamine recreationally.

All psychedelics have a degree of risk to them, which is why all startups in this space, including Seelos Therapeutics Inc. (NASDAQ: SEEL), are currently looking at the use of the drugs they are developing in a clinical setting only where experienced professionals can maximize the benefits patients derive while keeping the risk of side effects minimal or at zero level.

Seelos Therapeutics Inc. (SEEL), closed Thursday's trading session at $0.8678, up 7.0037%, on 510,058 volume. The average volume for the last 3 months is 461,715 and the stock's 52-week low/high is $0.4803/$1.52.

Hecla Mining Company (HL)

MarketClub Analysis, SmarTrend Newsletters, Schaeffer's, InvestorPlace, Wyatt Investment Research, StocksEarning,, MarketBeat, Top Pros' Top Picks, QualityStocks, TopStockAnalysts, StreetAuthority Daily, Market Report, The Street, Money Morning, Zacks,, Jason Bond, Daily Trade Alert, Kiplinger Today, Today's Financial News, StreetInsider, Wall Street Grand, Trades Of The Day, Streetwise Reports, TheStockAdvisors, StockOodles, Gryphon Digest, TradersPro, The Wealth Report, Stockhouse, SureMoney, National Inflation Association, Penny Detectives, TradingAuthority Daily, Darwin Investing Network, Options Elite, Penny Sleuth, Wall Street Daily, INO Market Report, The Growth Stock Wire, Profit Confidential, ProfitableTrading, ChartAdvisor, PennyStockLive, TraderPower, CRWEPicks, BestOtc, Barchart, Investing Futures, Investing Lab, CRWEFinance, Daily Markets, Forbes, DrStockPick, CRWEWallStreet, Daily Wealth, Investopedia, CustomerService, Greenbackers, Rockwell Trading, Weiss Research, WealthMakers, Wealth Insider Alert, TradingMarkets, Traders For Cash Flow, Trade of the Week, StockHotTips, StockEarnings, PennyOmega, SmallCapVoice, Investor Guide, Residual Income Report, PennyToBuck, AllPennyStocks, MonsterStocksPicks, Money and Markets,, InvestorGuide, Investor Update and Stock Stars reported earlier on Hecla Mining Company (HL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Investing in precious metals can seem like a pointless endeavor as gold and silver don’t generate interest and will not grow investments in any way. This is contrary to other asset classes that generate interest and dividends, allowing investors to steadily grow their investments and earn a passive income.

Such asset classes can be quite lucrative for investors, especially as the U.S. Federal Reserve has raised benchmark interest rates for several consecutive months and increased the potential earnings investors could earn from certain holdings.

So why would an investor who is new to the precious metals market invest their hard-earned cash in an asset class that doesn’t earn dividends or interest and won’t increase their investment?

Precious metals are an inflation hedge. One of the main reasons why seasoned investors store their money in precious metals is to protect it from inflation. Inflation is capable of reducing the value of money over time, meaning you will need more money to buy the same amount of goods and services than you needed before. With inflation and the cost of living rising across the country, investing in precious metals will allow you to preserve the value of your money and hit your long-term financial goals.

To diversify your portfolio. For investors, there is nothing as risky as putting all your eggs in the proverbial basket. Every investor is advised to diversify their portfolio and invest in a variety of stocks, mutual funds and bonds to protect themselves in case one asset class loses value.

You can choose to diversify by investing some of your savings in gold and silver. Even though these investments won’t generate any interest, they will offer you a degree of protection in case one or more of your other investments perform poorly.

To preserve your wealth. Most investors would like to preserve the wealth they have built over time. Unfortunately, even the strongest stocks underperform sometimes, meaning that your holdings are always at risk of devaluation. Not to mention the risk presented by economic upheaval and inflation that could essentially reduce the amount of money you have sitting in your accounts.

Investing in a tangible asset such as silver or gold instead of a fiat currency such as the U.S. dollar will protect your money from deflation and inflation, allowing you to preserve your wealth over time.

To pass down your wealth. Generational wealth plays a significant role in access to resources, financial security, and social mobility. If you are planning on passing on the wealth you have built to your descendants, investing in precious metals is the way to go. Countless families have used gold and silver to pass down wealth in the past, and storing your wealth in these precious metals will allow it to retain its value long after you are gone.

Many mining companies, including Hecla Mining Company (NYSE: HL), are focused on keeping the world supply of precious metals adequate, so there is no rush in doing your homework and deciding when you can or even should add these metals to your portfolio.

Hecla Mining Company (HL), closed Thursday's trading session at $6.22, off by 0.955414%, on 7,845,810 volume. The average volume for the last 3 months is 18,960 and the stock's 52-week low/high is $3.41/$7.66.

The QualityStocks Company Corner

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

NetworkNewsWire Editorial Coverage: It may seem hard to believe, but the first solar panels werereadily available to homeowners who could afford them in the early1980’s. Back then, the U.S. government was providing incentives totry and encourage consumer adoption. That focus on sustainabilityhas continued — and grown. Most recently, renewable natural gas(“RNG”), a carbon neutral alternative to traditional natural gasderived from organic waste, has been gaining substantial momentum.The honor for the first RNG facility in North America goes to EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) (Profile), which opened its first facility in British Columbia, Canada, morethan a decade ago. Whether investors are interested in solar, RNG,wind, green hydrogen or any other type of renewable energy that canreduce reliance on fossil fuels, now is a time to be excited. Inpart, that enthusiasm can be directly tied to the recent passage ofthe Inflation Reduction Act (“IRA”), which earmarked $369 billionfor infrastructure and incentives to accelerate the use ofrenewable energies in a bid to combat climate change. That’s bignews for companies such as EverGen, Brookfield Renewable Partners L.P. (NYSE: BEP), Clean Energy Fuels Corp. (NASDAQ: CLNE), Aemetis Inc. (NASDAQ: AMTX), Enphase Energy Inc. (NASDAQ: ENPH), and others emerging as stewards to slashing carbon emissions withinnovation.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Thursday's trading session at $2.2, up 1.3825%, on 11,450 volume. The average volume for the last 3 months is 11,450 and the stock's 52-week low/high is $1.365/$4.00.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused onmerging traditional therapeutics with psychedelic research, todayannounced that the U.S. Patent and Trademark Office (“USPTO”) hasissued U.S. Patent 11,491,120, titled “PharmacologicalProphylactics Against Stress-Induced Affective Disorders inFemales.” The patent’s allowed claims protect the use of portfoliodrug SPC-15 in a method of treating stress-induced affectivedisorders including anxiety and post-traumatic stress disorder(“PTSD”). With the patent, the company expands its intellectualproperty and technology rights for the treatment of rare diseases.“After a comprehensive review by USPTO, we are pleased with thescope of the granted claims offering further protection for ournovel SPC-15 technology and its market potential for anxiety, PTSDand related disorders,” said Silo’s Chief Executive Officer EricWeisblum.

To view the full press release, visit

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.


Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Thursday's trading session at $3.06, up 16.3498%, on 4,485,060 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.00/$.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and emergencysystems, announced that it has entered five new contracts outliningsales for 13 more machines. The momentum the company created lastyear is carrying into 2023. The new contracts include a Portlandprivate equity real estate investment firm, which signed a contractfor a K5 Autonomous Security Robot (“ASR”) to patrol the parkinggarage of a downtown skyscraper; an Ohio property management group,which selected a K5 ASR to patrol parking lots and surroundingareas of an outdoor entertainment and retail venue; a full-servicesecurity company, which is taking steps to become an authorizedKnightscope reseller; an emerging Knightscope Authorized Partnerthat ordered four 4 K5’s and preordered 4 K1 Hemisphere ASRs; anda current southern California university client, which is expandingits emergency communication system with additional K1 Blue Lightproducts.

To view the full press release, visit

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Thursday's trading session at $1.64, up 8.6093%, on 737,235 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.35/$12.3549.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of self-contained, automated,indoor “micro-farms” called GrowPods, has announced a new line ofautomated modular GrowPod systems. The new line is designed toexpand the GrowPod offerings to a wider range of customers andspecialty plant cultivations. The new systems, which are designedand built by GP Solutions, are also known as vertical farms, growrooms and container farms; each option creates a clean environmentthat allow plants can grow to their full potential. The newofferings include Flex Farm, a five-tier, five-channel growingsystem with a hand sink, nursery, and prep area; Hydro Farm, afive-tier hydroponic growing system with many of the same featuresas the Flex Farm but without the hand sink, nursery and prep area;Hybrid Farm, a unique system with a five-tier, three-channelgrowing system on one side and a three-tier flood table on theother side; Grow Max, a soil-based pod that comes in single, dualand triple-tier setups designed to use less water while maximizingyields; Entry Unit, a clean room that can be configured forprocessing, fertigation, or multiple other uses; and DP1 DryingUnit that features NSF-rated insulated walls, dehumidification,circulation fans, HVAC system and carbon filtration that providesan ideal environment for drying plants. The announcement notes thatthe new line of pods is modular and stackable, making the podsideal for an array of users, including farms, large commercialenterprises, nurseries, restaurants, grocery stores, nonprofits andmore. To view the full press release, visit

The past two decades have seen a plethora of states across thecountry vote on measures to legalize either the medical or recreational use of marijuana. By the end of 2022, dozens of states allowed medical marijuana within their borders while nearly 20states had legal recreational cannabis markets. These state-levelcannabis markets have been extremely lucrative for their homestates, generating billions of dollars in cannabis taxes andcreating hundreds of thousands of new job opportunities. Voters inOklahoma may soon be able to see some of this cannabis action after a measure to legalize cannabis was slated to be voted on inthe upcoming March ballot. The initiative in question, State Question 820, would allow thepossession and consumption of cannabis for individuals aged 21years and older. For those who want to grow their own cannabis oncethis measure passes and is implemented, lots of indoor cultivationequipment makers, including Advanced Container Technologies Inc. (OTC: ACTX), could be on hand to avail supplies to ensure they succeed intheir efforts.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Thursday's trading session at $0.44, up 10%, on 51,075 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.25.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

Although emotional support and service dogs may seem similar to theuninformed viewer, there are several critical differences between these two types of dogs. Dogs have been man’s best friendfor thousands of years, sticking with humans since the early daysof cave painting and stone tools, through the middle ages, theindustrial revolution and into the modern age. Dogs helped to protect human settlements from dangerous animals and other people; they were alsoinstrumental in guarding and herding livestock for thousands ofyears. While plenty of dogs around the world still serve thisfunction, most people use dogs for companionship these days.Emotional support and service dogs, however, provide more than justcompanionship and support to their owners. Service dogs, forstarters, are trained to specifically assist and perform certainduties for an individual with a disability. This includes seizure dogs that warn their owners of impending seizures, seeing-eye dogs that help lead visually impaired or blind people around obstacles,and dogs that help their owners cope with conditions such as regular anxiety attacks or post-traumatic stress disorder(PTSD). While these furry friends make great support or servicecompanions, they too can also face a number of health challenges,including seizures triggered by different conditions. A number ofcompanies such as India Globalization Capital Inc. (NYSE American: IGC) are devoting considerable resources to developing treatments forpet seizures so that humans can continue to have the companionshipand assistance that dogs can render.

A recent poll from Harvard CAPS-Harris has found that Americans favor looser regulations for marijuana and tighter rules for social media, cryptocurrencies, coal andelectric vehicles. The survey polled voters on a broad range ofnational issues and asked them if they thought the governmentshould regulate the issues more or less, or keep currentregulations as they are. Results indicate 45% of the surveyparticipants stated that cannabis should be regulated looser thanit is now, 22% said that cannabis regulations should stay as theyare, and 33% wanted tighter cannabis regulations. Compared to allthe other items in the poll, participants were more likely to saythat cannabis needs fewer regulations. An increasing number ofstates have moved to legalize cannabis for medical or recreationaluse over the past two decades, resulting in a massive industry thatgenerates billions of dollars in sales and taxes. With companiessuch as India Globalization Capital Inc. (NYSE American: IGC) engaged in developing drugs from THC and other cannabis compounds,the FDA guidance couldn’t have come sooner.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Thursday's trading session at $0.4, up 1.2658%, on 181,498 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$1.16.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, iscollaborating with Menzies Aviation and Loop Global Inc. on a pilotprogram at the Los Angeles International Airport; the programinvolves Mullen’s Class 1 EV cargo vans. The world’s largestaviation services company, Menzies operates in 250-plus airports in58 countries, providing ground, air cargo and fuel services tocommercial airports and airlines. Menzies is piloting MullenAutomotive electric vans and Loop Global charging infrastructureacross its operations at LAX; the program is part of Menziescommitment to identify innovative solutions as it works to becomecarbon neutral by 2033. According to the announcement, the 60-daypilot program will evaluate MULN’s Class 1 EV vans in several usecases across Menzies’ LAX operations. Loop will provide EV charginginfrastructure and fleet operations software to service the Mullenelectric vans through its electric vehicle fleet as-a-service(“EVFaaS”) program. Loop is one of the fastest-growing electricvehicle charging network infrastructure companies in the world.“Menzies is a well-respected leader in the aviation industry,” saidMullen Automotive CEO and chair David Michery in the press release.“Our commercial EVs are a natural fit for airport service andlogistics operations. Working together with Menzies and Loopproviding a full EV ecosystem solution is a great opportunity forMullen.”

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $0.381, up 8.4543%, on 290,659,507 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.18/$4.1799.

Recent News

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

  • For over 30 years, Coyuchi has provided sustainable luxury homegoods made from 100% organic cotton materials
  • Coyuchi is a founding member of the California Cotton &Climate Coalition, using cotton grown on farms that havetransitioned to Climate Beneficial practices which are believedto help increase resilience to drought, counter erosion, andbenefit the climate
  • The company’s future plans include expanding its catalog toinclude more sustainable products that cater toenvironmentally-conscious consumers

For three decades, Coyuchi, the gold standard in sustainable luxury home goods, has beendriven by four foundational pillars – protecting the planet,innovating circular design, sustainable living, and communityenrichment. Coyuchi’s line of products includes luxury organicbedding, sheets, towels, apparel, and other home goods, which areproduced using 100% organic cotton materials. With a seasonedleadership team, a robust e-commerce shopping experience, and ahealthy customer base, Coyuchi is preparing to enter a new phase ofgrowth as the world awakens to sustainability at scale.

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values ( With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through, creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News


GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

GeoSolar Technologies (“GST”), a climate technology company based in Colorado, aims to marketSmartGreen(TM) to over 120 million homes across the United Stateswith flexible options to build the system into new construction oradapt it to existing buildings. “GeoSolar Technologies helpshomeowners fully maximize the shift to electrification with itsSmartGreen whole-home renewable energy systems that leverageelectric power while lowering bills, reducing carbon emissions, andproviding unparalleled energy efficiency. Electrification isincreasingly presented as a solution to rising energy costs, makingSmartGreen a viable alternative that can either drastically loweror eliminate utility bills,” a recent article reads. “GeoSolar’sSmartGreen allows homeowners to leverage the benefit of an electricheat pump powered by geothermal ground loops. SmartGreenadditionally taps into the power of the sun through photovoltaicrooftop solar panels to provide all the electricity required by thehome to power appliances and charge electric vehicles. Besidesproviding homeowners with energy independence, SmartGreen improvesbuilding efficiency by upgrading insulation, windows, lightingsystems, and the building envelope.”

To view the full article, visit

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.


The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.


The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.

Recent News


Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed itspatented DehydraTECH(TM) technology, which is designed forformulating and delivering lipophilic (fat-soluble) drugs andactive ingredients. “DehydraTECH increases effectiveness andimproves how these ingredients enter the bloodstream. Benefits ofDehydraTECH include: improved speed of onset, with effects felt inminutes; increased bioavailability, with more of the drug deliveredinto the bloodstream; increased brain absorption, with testingsuggesting up to 10x improvement; and improved drug potency, withmore of the ingested product made available in the bloodstreamrequiring lower dosages,” a recent article reads. “Animal studiesconducted by Lexaria have demonstrated a propensity for DehydraTECHtechnology to elevate the quantity of drug delivered across theblood-brain barrier by as much as 1,900%, which has initiated newpatent applications and has opened the possibility of improved drugdelivery.”

To view the full article, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $3.01, off by 4.1401%, on 33,808 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.83.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing andcommercializing innovative immunotherapeutic products primarily forthe treatment of infectious and autoimmune diseases, todayannounced that its CEO Amir Reichman will present at the BIO CEO & Investor Conference. The event is slated to take place in New York from Feb. 6-9,2023. Reichman’s presentation, scheduled to begin at 4:15 p.m. ETon Feb. 6, will focus on recent successful preclinical in vivo results of BiondVax’sinnovative inhaled COVID-19 treatment. The presentation will also cover additional pipeline plans,including nanosized VHH-antibodies (“NanoAbs”) for the treatment ofautoimmune diseases, such as psoriasis, asthma, psoriatic arthritisand macular degeneration. Reichman and Mark Germain, BiondVax’s chairman of the board, will be available to meetpotential partners, collaborators and investors throughout theconference. Interested parties are encouraged to scheduleone-on-one appointments as detailed in the announcement.

To view the full press release, visit

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Thursday's trading session at $2.59, even for the day, on 80,933 volume. The average volume for the last 3 months is 328,458 and the stock's 52-week low/high is $2.37/$22.90.

Recent News

MetAlert Inc. (OTC: MLRT)

The QualityStocks Daily Newsletter would like to spotlight MetAlert Inc. (OTC: MLRT).

GPS-enabled location device developer MetAlert providesgeographical tracking technology that is discrete and functionalthrough shoe inserts that provide data connectivity to cognitivepatient caregivers

MetAlert announced in January that it is expanding the reach of itsSmartSole flagship product through an agreement with Sweden’sgovernment that was established by distribution partner Posifon AB

Government agencies across Europe and in the United States haverecognized the importance of being able to monitor the whereaboutsof patients with cognitive concerns

MetAlert’s development team has improved the SmartSole with abattery capable of lasting up to five days, and the company plansto roll out its -Plus model later this quarter with Bluetooth andWi-Fi capability for enhanced data monitoring of falls and othermedical concerns

Wearable tracking and health monitoring device developer MetAlert (OTC: MLRT) provides relief to the world’s elderly and medical patients proneto confusion through the company’s flagship product — an insertableshoe insole equipped with tech that transmits vital informationabout the wearer to caregivers.

MetAlert Inc. (OTC: MLRT) is a pioneer in location sensitive health monitoring devices (estimated $47 billion industry in 2021) and wearable technology products (industry forecast to reach $174 billion by 2030).

With over 20 years of experience and an extensive patent portfolio (30+), MetAlert is a leader for consumers/patients afflicted with Alzheimer’s, dementia, and autism (ADA). This market represents approximately 2.9% of the world’s population (approximately 34 million people in 24 developed countries). Due to specific behaviors (problems with memory, adversity to wearing unknown items, etc.) of consumers/patients in this market segment, traditional products, such as an iPhone or Fitbit, are not a practical solution. This has created a significant market with very few competitors for MetAlert.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, and selling products and services in GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. The company offers a global end-to-end hardware, software, and connectivity solution, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products and enterprise applications.

Using its award-winning, patented GPS SmartSole® as a hub for collecting and transmitting data to the cloud in real-time, MetAlert is expanding its value proposition to consumers and increasing its revenue per user (RPU) while creating the largest database of health statistics for ADA consumers/patients. MetAlert generates revenue from product sales, recurring subscriptions, intellectual property (IP) licensing, and professional services. The company has international distributors servicing customers in over 35 countries and is an approved U.S. military government contractor. Its customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers.

The company is headquartered in Los Angeles, California, with a sales office in London, England, and distributors across the globe.


  • GPS SmartSoles® HUB (launched Q4 2022) is a GPS/BLE-equipped insole that allows remote monitoring, data collection, and encrypted data transmission to the cloud.
    • Telehealth (available Q4 2022) allows access remotely to doctors and other health professionals on an as-needed basis. This service will also function as the prescribing doctor once Medicare reimbursement codes are established.
    • Concierge (available Q4 2022) provides 24/7/365 enhanced emergency response that coordinates with all relevant parties to quickly detect false alarms and escalate response as needed.
    • Bluetooth Enabled Devices (available Q1 2023) include third-party devices that collect vitals and other health data and connect with the GPS Smartsoles® HUB.
    • Artificial Intelligence (available Q1 2023) software will evaluate the Teradata of health information identifying trends and respond to preestablished alert thresholds.
  • Take-Along Tracker is a small GPS tracking device – less than three inches long – that works with 4G cellular service and will have the same “HUB” functionality as the GPS Smartsoles®. This versatile and affordable mini tracker boasts super long battery life, with up to 14 days of operation per charge.
  • RoomMate™ is a wall-mounted alert system that detects and alerts caregivers about patient behavior that could lead to falls and injuries. The system features 3D infrared and wall-mounted sensors, eliminating the need for any other physical installation or wearables. RoomMate™ offers patient privacy by design. Images are not stored, but all actions are logged. It’s a unique solution for looking after patients without intruding on their personal space.

Market Outlook

According to Grand View Research (Patient Monitoring Devices Market Size & Share Report, 2030), the global patient monitoring devices market size was valued at $47.0 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2030. The expansion of the industry can be attributed to the rise in demand for monitoring devices used to measure, distribute, record, and display a variety of biometric data, including blood pressure, temperature, and blood oxygen saturation level.

The growing number of chronic disorders, such as diabetes, stroke, and kidney disease, are driving the demand for patient monitoring devices. For instance, according to the World Health Organization (WHO), about 422 million people globally have diabetes. Likewise, the number of asthma and chronic obstructive pulmonary disease patients (COPD) is increasing rapidly.

According to the WHO, around 235 million people suffer from asthma. As a result, peak flow meters, which are used to gauge respiration rate, are increasingly used. The market for patient monitoring devices is driven by the simplicity with which it is handled, transported, and remotely accessible. Major market players are engaging in a variety of tactics to expand the industry, including partnerships, cooperation, innovation, launches, and mergers.

During the COVID-19 outbreak, social segregation and quarantining procedures were put into place worldwide. Many people avoided regular hospital visits as a result. Many people now need routine home temperature and oxygen level monitoring to maintain track of their health, thereby demanding monitoring devices at home.

Various government programs are supporting the pandemic outbreak. The FDA has granted Emergency Use Authorizations (EUAs) for a few wearables and patient monitoring devices to improve access to medicines, monitor patients more closely, and lessen the risk of SARS-CoV-2 exposure to medical professionals during the COVID-19 pandemic.

The growing popularity of wearable and remote patient monitoring devices is another factor fueling the market’s expansion. By fusing clinical symptomology with vital indicators, wearable technology helps in the diagnosis of many chronic diseases. Thus, there has been a dramatic rise in the usage of wearable technology to combat COVID-19.

The wearable medical device market is anticipated to reach $174.48 Billion by 2030, expanding at a 27.1% CAGR during the forecast period (2022-2030), according to Market Research Future.

MetAlert identifies the total addressable market for its wearable patient monitoring tech for those with Alzheimer’s, dementia, and autism at more than 34 million potential patients in North America, Europe, South Africa, and Asia.

Management Team

Patrick E. Bertagna is Founder, CEO and Chairman at MetAlert. He began his career in apparel sales in 1983 and was promoted to national sales manager within two years. In 1986, he founded his first company importing apparel from Europe and selling to U.S. retailers from JCPenney to Neiman Marcus. He has founded several technology and apparel companies, including MetAlert in 2002, which he took public in 2008. He attended Cal State University Northridge with a business major and a psychology minor.

Louis Rosenbaum is COO of MetAlert. He co-founded Global Trek Xploration and was an initial investor in MetAlert. He has successfully started companies in multiple industries, including apparel, environmental services, and the music industry, achieving annual revenues in the multi-millions of dollars. He previously was president of Elements, a women’s apparel company, and of Advanced Environmental Services.

Alex McKean is CFO at MetAlert. He is also the CFO of Encore Brands Inc., a position he has held since 2009. He has held positions as Controller and VP of Finance at 24:7 Film and, Director of FP&A/SVP at Franchise Mortgage Acceptance Company, Corporate Accounting Manager/Treasurer of Polygram Filmed Entertainment and Assistant Treasurer/Controller for State Street Bank. He holds an International MBA from Thunderbird School of Global Management and undergraduate degrees in business and political science from Trinity University.

MetAlert Inc. (OTC: MLRT), closed Thursday's trading session at $0.1694, off by 3.2553%, on 97,690 volume. The average volume for the last 3 months is 168,059 and the stock's 52-week low/high is $0.06/$1.00.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

SideChannel (OTCQB: SDCH), a leading provider of cybersecurity services and technology foremerging and mid-market companies, was recently featured on Fox Business. A segment aired on “Mornings with Maria” covers discussion regarding TikTok, which is owned by a Chinesecompany, and the platform’s potential security issues that will beaddressed by its CEO, who is set to testify before Congress nextmonth. TikTok was recently banned from use on U.S. governmentdevices, and American lawmakers are proposing to ban it outright.The piece addresses rising concerns from experts such asSideChannel’s CEO Brian Haugli, who previously served as acybersecurity leader with the U.S. Department of Defense. “We’reallowing a single organization that sits and is headquartered inChina to be able to go do this,” Haugli says, discussing themassive amounts of data collected and stored by the app from morethan 80 million active users in the U.S. alone. “That’s a concernnot just from me, as a person, a citizen who wants privacy, butbroader for society, especially the United States. Think about,‘what does the aggregate amount of this data actually represent inthe hands of someone who is viewed as a foreign adversary?’”

To view the segment, visit

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.


Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.


Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Thursday's trading session at $0.1021, off by 1.0659%, on 500 volume. The average volume for the last 3 months is 55,129 and the stock's 52-week low/high is $0.0675/$0.18.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.